Investigating the role and therapeutic potential of the alpha5beta1 integrin in risk factors for COVID-19-associated cognitive impairment

研究 α5β1 整合素在 COVID-19 相关认知障碍危险因素中的作用和治疗潜力

基本信息

  • 批准号:
    10658178
  • 负责人:
  • 金额:
    $ 225.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-04-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Rapidly emerging evidence has characterized the association between vascular dementia (VaD) and increased COVID-19 incidence, morbidity, and post-COVID cognitive decline. We theorize that brain vascular pathology in VaD and additional pathophysiologic features such as blood-brain barrier (BBB) disruption and reduced cerebral blood flow may directly contribute to both VaD and COVID-19. Several lines of evidence support this hypothesis. First, we have demonstrated that SARS-CoV-2 binds to the vascular integrin α5β1 receptor to infect cells, the same receptor we have also linked to BBB disruption in brain ischemia (stroke) models and chronic bilateral carotid artery stenosis (BCAS), which models pathophysiological aspects of VaD such as reduced cerebral blood flow, BBB disruption, neuroinflammation, white matter damage, and cognitive decline. Second, integrin α5β1 is substantially upregulated in an age-dependent fashion (aged>young) in the brain vasculature after stroke and BCAS, and inhibition of this receptor with the clinically-validated integrin α5β1 pentapeptide inhibitor ATN-161 lessens BBB disruption and cognitive impairment in these models. Third, SARS-CoV-2 infection also increases integrin α5β1 expression in vivo and disrupts the BBB. Forth, preliminary results suggest that SARS-CoV-2 infection after BCAS further increases morbidity vs. BCAS or infection alone and accelerates brain vascular integrin α5β1 upregulation. Fifth, ATN-161 inhibits SARS-CoV-2 infection in vitro and in vivo and prevents SARS- CoV-2-induced increased expression of α5β1 integrin. Finally, although angiotensin-converting enzyme 2 (ACE2) is the canonical receptor for viral entry (internalization and fusion) into host cells, its ectodomain binds the viral spike protein (S-protein) on the surface to facilitate virus attachment and access into host cells through receptor-mediated endocytosis using an RGD motif. As many cell-surface integrins also bind RGD, we and others have provided compelling evidence that integrins are co-receptors of the virus. Additionally, we have shown that talin-dependent integrin activation is required for SARS-CoV-2 infectivity. Consistent with our results, previous studies have shown that α5β1 and ACE2 engage in signaling crosstalk likely driven by mutual interaction at their cytoplasmic tails. Building on these findings, we hypothesize that (i) integrin α5β1 plays an important age-dependent pathogenic role in the association between SARS-CoV-2 infection and VaD by worsening pre-existing VaD after COVID-19, (ii) ATN-161 treatment before, during, or after COVID-19 infection will stabilize BBB integrity to improve COVID-19 neurocognitive outcomes in the context of pre-existing vascular dementia, and (iii) integrin α5β1 signaling regulates infectivity, and its upregulation potentiates dysregulation of the BBB. To investigate these hypotheses, we propose to 1). Demonstrate that experimental VaD worsens COVID-19 morbidity and subsequent cognitive decline, 2). Determine the therapeutic potential of integrin α5β1 inhibition in improving VaD post-COVID morbidity and cognitive decline, 3). Determine the signaling mechanism of integrin α5β1 required for SARS-CoV-2 productive infection and dysregulation of cell barrier function.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TIONE BURANDA其他文献

TIONE BURANDA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TIONE BURANDA', 18)}}的其他基金

Development of HTS Assays for Inhibitors of Viral-Cell Interactions
病毒-细胞相互作用抑制剂的 HTS 检测方法的开发
  • 批准号:
    8049411
  • 财政年份:
    2010
  • 资助金额:
    $ 225.41万
  • 项目类别:
Spatiotemporal Regulation of Membrane Raft Trafficking in Virus Activated Cells
病毒激活细胞膜筏运输的时空调控
  • 批准号:
    8204961
  • 财政年份:
    2010
  • 资助金额:
    $ 225.41万
  • 项目类别:
Spatiotemporal Regulation of Membrane Raft Trafficking in Virus Activated Cells
病毒激活细胞膜筏运输的时空调控
  • 批准号:
    8028735
  • 财政年份:
    2010
  • 资助金额:
    $ 225.41万
  • 项目类别:
Membrane Organization in Cell Signaling and Adhesion
细胞信号传导和粘附中的膜组织
  • 批准号:
    7382599
  • 财政年份:
    2004
  • 资助金额:
    $ 225.41万
  • 项目类别:
Membrane Organization in Cell Signaling and Adhesion
细胞信号传导和粘附中的膜组织
  • 批准号:
    6866410
  • 财政年份:
    2004
  • 资助金额:
    $ 225.41万
  • 项目类别:
Membrane Organization in Cell Signaling and Adhesion
细胞信号传导和粘附中的膜组织
  • 批准号:
    7194318
  • 财政年份:
    2004
  • 资助金额:
    $ 225.41万
  • 项目类别:
Membrane Organization in Cell Signaling and Adhesion
细胞信号传导和粘附中的膜组织
  • 批准号:
    6769778
  • 财政年份:
    2004
  • 资助金额:
    $ 225.41万
  • 项目类别:
Membrane Organization in Cell Signaling and Adhesion
细胞信号传导和粘附中的膜组织
  • 批准号:
    7015037
  • 财政年份:
    2004
  • 资助金额:
    $ 225.41万
  • 项目类别:

相似国自然基金

新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介 导“肠-胰岛 ”轴血糖调控功能的降糖机制研 究
  • 批准号:
    Y24H280055
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
  • 批准号:
    82330111
  • 批准年份:
    2023
  • 资助金额:
    220 万元
  • 项目类别:
    重点项目
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
  • 批准号:
    82373169
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
  • 批准号:
    32300137
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
  • 批准号:
    32302080
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
  • 批准号:
    82305171
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
刺参自溶引发机制中ACE2调控靶点的调控网络研究
  • 批准号:
    32372399
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
Spike变异对新冠病毒抗原性及ACE2种属嗜性的影响研究
  • 批准号:
    82272305
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目

相似海外基金

新型コロナウイルス感染阻害能を有する抗ACE2抗体の阻害機構に関する構造基盤解明
阐明具有抑制新型冠状病毒感染能力的抗ACE2抗体抑制机制的结构基础
  • 批准号:
    24K09338
  • 财政年份:
    2024
  • 资助金额:
    $ 225.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ACE2のユビキチン化を介したコロナウイルス感染機構の解明と創薬への挑戦
通过ACE2泛素化阐明冠状病毒感染机制和药物发现的挑战
  • 批准号:
    22KJ2499
  • 财政年份:
    2023
  • 资助金额:
    $ 225.41万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
ACE2阻害薬およびERK経路阻害薬による慢性腎炎進展抑制効果の検証
ACE2抑制剂和ERK通路抑制剂抑制慢性肾炎进展的效果验证
  • 批准号:
    23K14982
  • 财政年份:
    2023
  • 资助金额:
    $ 225.41万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Large-scale compatibility assessments between ACE2 proteins and diverse sarbecovirus spikes
ACE2 蛋白和多种 sarbecovirus 尖峰之间的大规模兼容性评估
  • 批准号:
    10722852
  • 财政年份:
    2023
  • 资助金额:
    $ 225.41万
  • 项目类别:
一次線毛とコロナウイルス感染におけるACE2の役割の解明
阐明 ACE2 在原发菌毛和冠状病毒感染中的作用
  • 批准号:
    22KF0004
  • 财政年份:
    2023
  • 资助金额:
    $ 225.41万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
The regulatory roles of ACE2 and its interaction with Nrf2 in arsenic-induced endothelial dysfunction in experimental and epidemiological studies
实验和流行病学研究中 ACE2 的调节作用及其与 Nrf2 的相互作用在砷诱导的内皮功能障碍中的作用
  • 批准号:
    23K16310
  • 财政年份:
    2023
  • 资助金额:
    $ 225.41万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Role of ACE2 in the mechanism of intestinal regeneration
ACE2在肠道再生机制中的作用
  • 批准号:
    23K15078
  • 财政年份:
    2023
  • 资助金额:
    $ 225.41万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Research and development of a novel pediatric anti-obesity medicine via ACE2 activation in DIZE
通过 DIZE 中 ACE2 激活研发新型儿科抗肥胖药物
  • 批准号:
    23K15417
  • 财政年份:
    2023
  • 资助金额:
    $ 225.41万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Lung delivery of novel ACE2 variants for COVID-19
针对 COVID-19 的新型 ACE2 变体的肺部输送
  • 批准号:
    10483042
  • 财政年份:
    2022
  • 资助金额:
    $ 225.41万
  • 项目类别:
ACE2 on gut barrier dysfunction and BRB disruption
ACE2 对肠道屏障功能障碍和 BRB 破坏的影响
  • 批准号:
    10535485
  • 财政年份:
    2022
  • 资助金额:
    $ 225.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了